Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Sienna Cancer Diagnostics (SDX) has raised approximately $1.7 million to accelerate commercialisation of SIEN NET and fund co-development expenditures
  • The company issued approximately 47 million shares were issued today at a price of 3.5 cents per share
  • Sienna will also offer eligible shareholders the opportunity to participate in a rights issue offer at the same price as the placement
  • On market close, Sienna remains steady on the market today and is selling shares for 3¢ apiece

Sienna Cancer Diagnostics (SDX) has raised approximately $1.7 million to accelerate commercialisation of SIEN NET and fund co-development expenditures.

The company issued approximately 47 million shares were issued today at a price of 3.5 cents per share.

Sienna is an Australian medical technology company with operations in the United States, Europe, Asia, Latin America and Australia.

Sienna’s most recent technology acquisition was a unique technology for the capture and isolation of target analytes in liquid biopsy samples.

The sample preparation technology, known as SIEN-NET, can accurately and rapidly prepare samples for the liquid biopsy testing of a range of clinically useful biomarkers including exosomes, lipids, proteins, and other molecular targets of interest.

Some of the funds will be used to accelerate the commercialisation of SIEN NET.

Funds will also be used to fund co-development expenditures for the development of a pancreatic cancer test and the development of an exosome-based therapeutics for the treatment for critical limb ischemia.

Sienna will also offer eligible shareholders the opportunity to participate in a rights issue offer at the same price as the placement.

Shareholders could also be able to apply for additional shares in excess of their rights using the personalised form.

On market close, Sienna remains steady on the market today and is selling shares for 3¢ apiece.

SDX by the numbers
More From The Market Herald

" Fisher & Paykel (ASX:FPH) flags softer profits for first half of FY23

Fisher & Paykel Healthcare (ASX:FPH) has forecast weaker revenue and profits for the half-year to the…

" Invex Therapeutics (ASX:IXC) receives FDA approval for third-phase Presendin clinical trial

Invex Therapeutics (ASX:IXC) has been given the tick of approval in the US for the development…
The Market Herald Video

" Mayne Pharma (ASX:MYX) CEO to retire following role relocation to the US

Mayne Pharma (ASX:MYX) CEO Scott Richards to retire following the company's decision to relocate the CEO…

" Emyria (ASX:EMD) receives positive screening results for MDMA-inspired analogues

Emyria (ASX:EMD) has received positive screening results from its MDMA novel drug discovery program with the…